The opening post put the caveat in the right place and I want to underline it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.
The general case is well covered; this is the awkward specific one.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
One of those cases where knowing the mechanism does not help the decision.
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
Marking that as an opinion rather than a finding.
Nicotinamide adenine dinucleotide preparations are not peptides at all and the certificate conventions are completely different. Reading one as though it were a peptide certificate produces confusion in both directions.
Reading rather than answering, but this is the post I would point somebody at.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
It is worth stating the boring hypothesis before the interesting one.
Read the full topic (166 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…
|
+100 | 108 | 1.3k | 8mo |
|
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. I was wrong about naming conventions for research…
|
+21 | 25 | 4.9k | 22d |
|
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since What changes if the standard account of catalogue breadth is wrong? I ask…
|
+62 | 66 | 26k | 10mo |
|
Compounds this community declines to help with, and why — does this still hold?
Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post,…
|
+3 | 7 | 26k | 7h |
|
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…
|
+81 | 87 | 35k | 10mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Oral contraceptives and delayed emptying: what the data shows
Oral contraceptives and delayed emptying: what the data shows — setting out what I have, and where I think it stops being reliable. A follow-up question about Oral contraceptives and delayed emptying that I…
|
+31 | 35 | 13k | 18mo |
|
Reading an interaction checker output critically
On the subject in the title: Reading an interaction checker output critically Working notes rather than a conclusion. A question about reading an interaction checker output that I think has a definite answer,…
|
+144 | 152 | 3k | 4mo |
|
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since…
|
+28 | 32 | 640 | 13mo |
|
Revisiting: What a well-designed human trial of a secretagogue would look like
On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Something about well-designed human trial does not reconcile…
|
+69 | 74 | 25k | 18mo |
|
Second pass at: Why this subcategory is stricter about sourcing than most
Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. A comparison question rather than a question about one compound.…
|
+120 | 129 | 61k | 11mo |